PVR and cancer: Recently, the IC axis involving the poliovirus receptor (PVR, CD155), poliovirus receptor-like 2 (PVRL2, CD112), and T cell immunoreceptor with Ig and ITIM domains (TIGIT) has emerged as a promising target for cancer immunotherapy [13].